{
    "title": "Women and AIDS Research Initiative Amendments of 1993",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Women and AIDS Research Initiative \nAmendments of 1993''.\n\nSEC. 2. ESTABLISHMENT OF GENERAL PROGRAM OF RESEARCH REGARDING WOMEN \n              AND ACQUIRED IMMUNE DEFICIENCY SYNDROME.\n\n    Part B of title XXII of the Public Health Service Act (42 U.S.C. \n800cc-11 et seq.) is amended by adding at the end the following \nsection.\n\n``SEC. 2321. RESEARCH REGARDING WOMEN.\n\n    ``(a) In General.--With respect to cases of infection with the \nhuman immunodeficiency virus, the Secretary shall establish a program \nfor the purpose of conducting biomedical and behavioral research on \nsuch cases in women, including research on the prevention of such \ncases. The Secretary may conduct such research directly, and may make \ngrants to public and nonprofit private entities for the conduct of the \nresearch.\n    ``(b) Certain Forms of Research.--In carrying out subsection (a), \nthe Secretary shall provide for research on--\n            ``(1) the manner in which the human immunodeficiency virus \n        is transmitted to women, including the relationship between \n        cases of infection with such virus and other cases of sexually \n        transmitted diseases, and clinical trials which examine the \n        question of the how the level of HIV infection can be prevented \n        by finding and treating sexually transmitted diseases in women;\n            ``(2) measures for the prevention of exposure to and the \n        transmission of such virus, including research on--\n                    ``(A) the prevention of any sexually transmitted \n                disease that may facilitate the transmission of the \n                virus;\n                    ``(B) rapid, inexpensive, easy-to-use sexually \n                transmitted disease diagnostic tests for women;\n                    ``(C) inexpensive single dose therapy for treatable \n                sexually transmitted diseases;\n                    ``(D) the development of methods of prevention for \n                use by women; and\n                    ``(E) the development and dissemination of \n                prevention programs and materials whose purpose is to \n                reduce the incidence of substance abuse among women;\n            ``(3) the development and progression of symptoms resulting \n        from infection with such virus, including research regarding \n        gynecological infections as well as breast changes, hormonal \n        changes, and menses and menopause changes, whose occurrence \n        becomes probable as a result of the deterioration of the immune \n        system;\n            ``(4) the treatment of cases of such infection, including \n        clinical research; and\n            ``(5) behavioral research on the prevention of such cases \n        and research on model educational programs for such prevention.\n    ``(c) Clinical Trials.--\n            ``(1) Gynecological evaluations.--In clinical trials under \n        this title in which women participate as subjects, the \n        Secretary shall ensure that--\n                    ``(A) each female subject who is infected with the \n                human immunodeficiency virus--\n                            ``(i) undergoes a gynecological examination \n                        as part of the evaluation of the medical status \n                        of the woman prior to participation in the \n                        trial; and\n                            ``(ii) receives appropriate follow-up \n                        services regarding such examination; and\n                    ``(B) the results of the gynecological examinations \n                are analyzed to determine the relationship between \n                gynecological conditions and the infection with such \n                virus.\n            ``(2) Standard treatments for gynecological conditions.--\n        The Secretary shall conduct or support clinical trials under \n        subsection (a) to determine whether standard methods of \n        treating gynecological conditions are effective in the case of \n        such conditions that arise as a result of infection with the \n        human immunodeficiency virus.\n            ``(3) Effectiveness of certain treatment protocols.--With \n        respect to cases of infection with the human immunodeficiency \n        virus, the Secretary shall conduct or support clinical trials \n        under subsection (a) to determine whether treatment protocols \n        approved for men with such cases are effective for women with \n        such cases.\n            ``(4) Support services.--\n                    ``(A) In conducting or supporting clinical trials \n                under this title in which women participate as \n                subjects, the Secretary shall provide the women with \n                such transportation, child care, and other support \n                services (including medical and mental health services, \n                treatment for drug abuse, and social services), \n                including services addressing domestic violence as may \n                be necessary to enable the women to participate as such \n                subjects.\n                    ``(B) Services under subparagraph (A) shall include \n                services designed to respond to the particular needs of \n                women with respect to participation in clinical trials \n                under this title, including, as appropriate, training \n                of the individuals who conduct the trials.\n    ``(d) Prevention Programs.--\n            ``(1) Sexual transmission.--\n                    ``(A) With respect to preventing the sexual \n                transmission of the human immunodeficiency virus, the \n                Secretary shall conduct or support research under \n                subsection (a) on barrier methods for the prevention of \n                sexually transmitted diseases, including HIV disease, \n                that women can use without their sexual partner's \n                cooperation or knowledge.\n                    ``(B) In carrying out subparagraph (A), the \n                Secretary shall give priority to identified research \n                needs and opportunities identified at the National \n                Institutes of Health sponsored meeting on Development \n                of Topical Microbicides that was held in May of 1993, \n                including research on--\n                            ``(i) the early stages in infectious \n                        processes;\n                            ``(ii) the identification, formulation and \n                        preclinical evaluation of new preparations;\n                            ``(iii) clinical testing for safety and \n                        efficacy; and\n                            ``(iv) studies concerning the acceptability \n                        and compliance of safe, effective microbicides.\n            ``(2) Epidemiological research.--The Secretary shall \n        conduct or support epidemiological research under subsection \n        (a) to determine the factors of risk regarding infection with \n        the human immunodeficiency virus that are particular to women, \n        including research regarding--\n                    ``(A) the use of various contraceptive methods;\n                    ``(B) the use of tampons;\n                    ``(C) the relationship between such infection and \n                other sexually transmitted diseases;\n                    ``(D) the relationship between such infection and \n                various forms of substance abuse (including use of the \n                form of cocaine commonly known as crack); and\n                    ``(E) the relationship between such infection and \n                sexual activity.\n    ``(e) Interagency Study.--With respect to the study being carried \nout by the Secretary (as of June 1993) through various agencies of the \nPublic Health Service for the purpose of monitoring the progression in \nwomen of infection with the human immunodeficiency virus, and \ndetermining whether such progression is different in women than in men, \nwhich study is known as the Women's Interagency HIV Study, the \nfollowing applies:\n            ``(1) The Secretary shall ensure that not less than 5,000 \n        women with such infection are included in the study.\n            ``(2) The Secretary shall provide for an increase in the \n        number of sites at which the study is to be conducted.\n            ``(3) The Secretary shall ensure that the study period is \n        for a minimum of 8 years.\n            ``(4) With respect to the human cells commonly known as CD4 \n        cells, the Secretary shall ensure that the study adequately \n        addresses the relationship between the number of such cells and \n        other markers in women with such infection and the development \n        of serious illnesses in such women. For purposes of the \n        preceding sentence, the study shall address gynecological \n        conditions, and other conditions particular to women, that are \n        not currently included in the list of conditions arising from \n        such infection that, for surveillance purposes, is maintained \n        by the Director of the Centers for Disease Control and \n        Prevention.\n    ``(f) Definition.--For purposes of this section, the term `human \nimmunodeficiency virus' means the etiologic agent for acquired immune \ndeficiency syndrome.\n    ``(g) Authorizations of Appropriations.--\n            ``(1) Clinical trials.--\n                    ``(A) For the purpose of carrying out subsection \n                (c)(1), there are authorized to be appropriated \n                $20,000,000 for fiscal year 1994, and such sums as may \n                be necessary for each of the fiscal years 1995 through \n                1996.\n                    ``(B) For the purpose of carrying out subsection \n                (c)(2), there are authorized to be appropriated \n                $10,000,000 for fiscal year 1994, and such sums as may \n                be necessary for each of the fiscal years 1995 through \n                1996.\n                    ``(C) For the purpose of carrying out subsection \n                (c)(3), there are authorized to be appropriated \n                $10,000,000 for fiscal year 1994, and such sums as may \n                be necessary for each of the fiscal years 1995 through \n                1996.\n                    ``(D) For the purpose of carrying out subsection \n                (c)(4), there are authorized to be appropriated \n                $15,000,000 for fiscal year 1994, and such sums as may \n                be necessary for each of the fiscal years 1995 and \n                1996.\n            ``(2) Prevention programs.--\n                    ``(A) For the purpose of carrying out subsection \n                (d)(1), there are authorized to be appropriated \n                $30,000,000 for fiscal year 1994, and such sums as may \n                be necessary for each of the fiscal years 1995 through \n                1996.\n                    ``(B) For the purpose of carrying out subsection \n                (d)(2), there are authorized to be appropriated \n                $10,000,000 for fiscal year 1994, and such sums as may \n                be necessary for each of the fiscal years 1995 through \n                1996.\n            ``(3) Interagency study.--For the purpose of carrying out \n        subsection (e), there are authorized to be appropriated \n        $15,000,000 for fiscal year 1994, and such sums as may be \n        necessary for each of the fiscal years 1995 through 1996.''."
}